BDC-3042
- Generic Name
- BDC-3042
Study of BDC-3042 As Single Agent and in Combination with Cemiplimab in Patients with Advanced Malignancies
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast CancerColorectal CancerClear Cell Renal Cell CarcinomaMelanomaHead and Neck CancerOvarian CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 147
- Registration Number
- NCT06052852
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath